On December 30, 2015, the board of directors of OncBioMune Pharmaceuticals, Inc. elected Daniel S. Hoverman as a member of the Board. Mr. Hoverman is a Director and senior member in Houlihan Lokey, Inc.'s Mergers & Acquisitions Group, where he advises companies on sale, financing and other strategic corporate transactions. Prior to joining Houlihan Lokey in 2010, Mr. Hoverman was a Director with Credit Suisse in Hong Kong in the Office of the General Counsel, and a Director with UBS in New York in the Equity Capital Markets Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% |
|
0.00% | -93.33% |
1st Jan change | Capi. | |
---|---|---|
-93.33% | 615K | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- THER Stock
- News Theralink Technologies, Inc.
- OncBioMune Pharmaceuticals, Inc. Elects Daniel S. Hoverman as Member of the Board